Fast™
Identification of at-risk NASH patients
Learn more
NewFibroScan® GO
The state-of-the-art non-invasive solution for liver disease management, affordable to all.
Powered by LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.
Supported by 3,500+ peer reviewed publications and 160+ guidelines.
An affordable solution…
Comprehensive and flexible pay-per-exam offer.
All services included.
…to assist in liver health management
Screening of at-risk patients for early intervention.
Supports physician ability to make instant medical decisions for patients.
Repeatable, reproducible, and consistent results.
Assists in monitoring staged progression of liver disease which may lead to improved patient outcomes.
A comprehensive solution at the point-of-care
Easily integrates into an office-based practice with small footprint and connectivity.
Enhanced clinical decision support with the Interpretation Guide and Scores by Echosens available on myFibroScan app.
A smaller, mobile equipment for multi-site configuration.
Centralized and secure data management on Echosens Cloud.
User management and exam activity monitoring.
A state-of-the-art FibroScan®
Quickly and easily assess liver stiffness using LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.1,2
Tried & Trusted
Without FibroScan® technology, we felt that our patients would be missing an important service and that many patients with advanced liver disease and significant health risk would go unrecognized.
Patients who get a FibroScan® love the fact that they now have understandable parameters of their NAFLD and NASH, or even just their transient elastography or fibrosis score.
A complete solution including proactive and dedicated support
Assists with onsite installation and training.
Includes maintenance, annual calibration of probes and both software upgrades and updates.
Easy access to continuous training and users community with Echosens Academy.
myFibroScan : Your everyday Fibroscan® companion
With myFibroScan interpret in just a few clicks the FibroScan® examination results and access the FibroScan® – based Scores.
Equipment compatible with an S+ probe (sold separately).
The FibroScan® 230 is intended to provide shear wave speed measurements and estimates of tissue stiffness as well as ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body. The Shear wave speed and stiffness measurements may be used as an aid to clinical management of adult patients with liver disease. FibroScan® 230 is indicated for non-invasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as determining a 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter). Shear wave speed, stiffness and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver. Shear wave speed, stiffness and CAP may be used as an aid in the clinical management of pediatric patients with liver disease.
1. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
2. Steadman R, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158.